Treatment of Deep Vein Thrombosis via Targeted Inhibition of the FXII-uPAR-pAkt2 Axis in Neutrophils
Congressional District Code:
Biomedical Laboratory R&D
October 2019 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
The overall goal of this proposal is to establish a targeted therapeutic strategy to disrupt the interaction of coagulation factor FXII (FXII) and urokinase plasminogen activator receptor (uPAR) to downregulate Akt2- mediated neutrophil activation for treatment of deep vein thrombosis (DVT). DVT is a leading cause of cardiovascular death. New anticoagulation therapies have been developed, however these therapeutic advances are all associated with increased rate of bleeding. Moreover, these curre...